Annual General Meeting 2017 - Fresenius · Fresenius Medical Care: The leader in dialysis for over...
Transcript of Annual General Meeting 2017 - Fresenius · Fresenius Medical Care: The leader in dialysis for over...
Quirónsalud: Market and quality leader in Spain
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 2
44 hospitals
~6,600 beds
320,000 inpatients
9.4 million outpatients
As of March 31, 2017
Fresenius Helios: Continued strong commitment to Germany
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 3
112 hospitals
~35,000 beds
1.3 million inpatients
3.9 million outpatients
As of March 31, 2017
Fresenius Medical Care: The leader in dialysis for over 20 years
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 4
In 2016
~140 million dialyzers
>48,000 dialysis machines
>3,600 dialysis clinics
>300,000 patients
Fresenius Kabi: Strong growth in all areas
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 5
In 2016
~80 new I.V. generics
€322 million in investments
~70 production sites
>1 billion infusion solutions
Fresenius Vamed: Continued geographic expansion
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 6
Well-balanced revenue distribution in 2016
Services49%
Sales:€1,160 m
Projects51%
Order intake >€1 billion
>800 projects since founding
in ~80 countries
Services for >600 hospitals
In 2016
2015 2016
13th consecutive record year
7
Sales Net incomeEBIT
+5% +9% +12%
According to US-GAAP; in part before special items
2015 2016 2015 2016
€m
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA
27,62629,083
3,958
4,3271,593
1,423
24th consecutive dividend increase
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 8
2
1619
22 23 2529
32
37
4244
55
62
1993 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
2016: Proposed(in euro cents)
CAGR+16%
Fresenius outperforms DAX index
54%
7%
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 9
13%
Share price development in 2016
A steadily growing Fresenius workforce
263,957Employees worldwide
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 10
104,872
149,351
232,873
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016As ofMarch 31, 2017
An excellent start in 2017
11
+19% +27% +28%
2015 2016
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA
Q1/16 Q1/17 Q1/16 Q1/17Q1/16 Q1/17
Sales Net incomeEBIT
€m
457
358
1,216
959
8,362
7,015
Group outlook 2017: Double-digit sales and earnings growth
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 12
2017:Sales +15-17%Net income +19-21%
Constant currency, according to IFRS, net income before special items
Strategic acquisitions for further growth
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 13
• Provider of generic pharmaceuticals
• Plants in the USA, Switzerland and India
• New dosage forms such as eye-drops, creams and sprays
• New treatment areas, for example ophthalmology and dermatology
• “Similar” to its already approved biologic originator drug, a biosimilar is produced using living cells
• Much less expensive than original preparations
• Ideal time to enter biosimilars
• Importance in medicine has been growing steadily
• Many similarities to conventional generics
Ambitious mid-term targets
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 14
2020:Sales €43-€47 bnNet income €2.4-€2.7 bn
Fresenius Helios: Learning from the best
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 15
Fresenius Medical Care: World’s largest dialysis provider
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 16
Fresenius Kabi: Investing in quality
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 17
Fresenius Vamed: Projects around the world
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 18
Fresenius: Better medicine for more people
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 19
Safe Harbor Statement
This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.
Annual General Meeting | May 12, 2017 | © Fresenius SE & Co. KGaA 20